



Veterinary  
Medicines  
Directorate

United Kingdom  
Veterinary Medicines Directorate  
Woodham Lane  
New Haw  
Addlestone  
Surrey KT15 3LS

**NATIONAL PROCEDURE**

**PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A PROPOSED  
VETERINARY MEDICINAL PRODUCT**

Arocenia 10 mg/ml Solution for Injection for Dogs and Cats

**Date Created: January 2024**

## MODULE 1

### PRODUCT SUMMARY

Name, strength and pharmaceutical form	Arocenia 10 mg/ml Solution for Injection for Dogs and Cats
Applicant	KRKA, d.d., Novo mesto Šmarješka cesta 6 8501 Novo mesto Slovenia
Active substance	Maropitant (as its citrate, monohydrate)
ATC Vetcode	QA04AD90
Target species	Dogs and Cats
Indication for use	<p>Dogs</p> <ul style="list-style-type: none"><li>• For the treatment and prevention of nausea induced by chemotherapy.</li><li>• For the prevention of vomiting except that induced by motion sickness.</li><li>• For the treatment of vomiting, in combination with other supportive measures.</li><li>• For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the <math>\mu</math>-opiate receptor agonist morphine.</li></ul> <p>Cats</p> <ul style="list-style-type: none"><li>• For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.</li><li>• For the treatment of vomiting, in combination with other supportive measures.</li></ul>

## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

[www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed)

## MODULE 3

### PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of conclusion of the procedure	26/10/2023

#### I. SCIENTIFIC OVERVIEW

#### II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS

##### ***II.A. Composition***

The product contains Maropitant (as its citrate, monohydrate) at a concentration 10 mg per ml and the excipients are sulfobutylbetadex and benzyl alcohol.

The container/closure system consists of Type I amber glass vials closed with bromobutyl stoppers. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and the presence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

##### ***II.B. Description of the Manufacturing Method***

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of mixing of the bulk solution, filtration, filling, sealing and sterilization.

Process validation data on the product have been presented in accordance with the relevant European guidelines

### ***II.C. Control of Starting Materials***

The active substance is Maropitant (as its citrate, monohydrate) an established active substance described in the ASMF. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

#### ***II.C.4. Substances of Biological Origin***

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

### ***II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process***

Not applicable

### ***II.E. Control Tests on the Finished Product***

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification. Control tests on the finished product are appropriate to adequately control the quality of the pharmaceutical form.

### ***II.F. Stability***

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

## ***G. Other Information***

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging: 60 days

### **III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACOTOXICOLOGICAL)**

#### ***III.A Safety Documentation***

##### ***Pharmacological Studies***

As this is a generic application in accordance with Article 13(1) of the Directive 2001/82/EC as amended, the bioequivalence with a reference product has been demonstrated, results of pharmaco-toxicological tests are not required.

##### ***Toxicological Studies***

Not applicable due to the legal basis of the product

##### ***User Safety***

A user risk assessment was provided in compliance with the relevant guidelines.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:

- People with known hypersensitivity to maropitant should administer the veterinary medicinal product with caution.
- Wash hands after use.
- In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician. In laboratory studies, maropitant has been shown to be a potential eye irritant.
- In the case of accidental eye exposure, flush the eyes with plenty of water and seek medical attention.

##### ***Environmental Safety***

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP guidelines.

##### **Phase I:**

The product will only be used in non-food animals and as a result environmental exposure will be low. A Phase II ERA was not required.

### **IV. CLINICAL DOCUMENTATION**

As this is a generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required.

## **V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics the benefit/risk profile of the product is favourable.

## **MODULE 4**

### **POST- AUTHORISATION ASSESSMENTS**

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

([www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed))

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

([www.gov.uk/check-animal-medicine-licensed](http://www.gov.uk/check-animal-medicine-licensed))